Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 31, 2025

Investing Legend Warren Buffett Bids Adieu to Wall Street, While His Trillion-Dollar Company, Berkshire Hathaway, Enters a New Era

View original at nasdaq.com
Investing Legend Warren Buffett Bids Adieu to Wall Street, While His Trillion-Dollar Company, Berkshire Hathaway, Enters a New Era Key Points Beginning Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Great businesses with sustainable moats and phenomenal management teams will excel over the long run

    80% confidence

  • S&P 500 has never had a rolling 20-year period where it delivered negative total returns, including dividends

    80% confidence

  • Vowed to continue Berkshire's buyback program when appropriate

    80% confidence

  • Never bet against America because U.S. economy and major stock indexes will increase in value over long periods

    80% confidence

  • Netflix investment of $1,000 on December 17, 2004 would be worth $507,744

    80% confidence

  • Nvidia investment of $1,000 on April 15, 2005 would be worth $1,153,827

    80% confidence

  • Stock Advisor's total average return is 983% compared to 195% for S&P 500

    80% confidence

Data points we hold from this source

New York Stock Exchange · average holding period5.5 months
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Investing Legend Warren Buffett Bids Adieu to Wall Street, While His Trillion-Dollar Company, Berkshire Hathaway, Enters a New Era — Source | Via News | ViaNews EU